key: cord-0937944-zaz5jwca
authors: Verma, Sonam; Joshi, Chetanchandra S.; Silverstein, Rachel B.; He, Mai; Carter, Ebony B.; Mysorekar, Indira U.
title: SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system
date: 2021-04-13
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.04.009
sha: ae8f9cf2c809c42d1afb1ea5a11fe0e76f716850
doc_id: 937944
cord_uid: zaz5jwca

Background SARS-CoV-2 infection appears to increase the risk of adverse pregnancy outcomes such as preeclampsia in pregnant women. The mechanism(s) by which this occurs remains unclear. Methods We investigated the pathophysiology of SARS-CoV-2 at maternal-fetal interface in pregnant women who tested positive for the virus using RNA in situ hybridization (viral RNA), immunohistochemistry, and hematoxylin and eosin staining. To investigate whether viral infection alters the renin angiotensin system (RAS) in placenta which controls blood pressure, we treated human trophoblasts with recombinant Spike protein or a live modified virus with a vesicular stomatitis viral backbone expressing Spike protein (VSV-S). Findings Viral colonization was highest in maternal decidua, fetal trophoblasts, Hofbauer cells, and in placentas delivered prematurely. We localized SARS-CoV-2 to cells expressing Angiotensin-converting enzyme 2 (ACE2), and demonstrate that infected placentas had significantly reduced ACE2. In response to both Spike protein and VSV-S, cellular ACE2 decreased while Angiotensin II receptor type 1 (AT1R) increased with concomitant increase in soluble fms-like tyrosine kinase-1(sFlt1). Viral infection decreased pro-angiogenic factors, AT2R and Placental growth factor, which competitively binds to sFlt1. Sera from infected pregnant women had elevated levels of sFlt1 and Angiotensin II type 1-Receptor Autoantibodies prior to delivery, both signatory markers of preeclampsia. Conclusions SARS-CoV-2 colonizes ACE2-expressing maternal and fetal cells in the placenta. Infection in pregnant women correlates with alteration of placental RAS. As RAS regulates blood pressure, SARS-CoV-2 infection may thus increase adverse hemodynamic outcomes such as preeclampsia in pregnant women. Funding NIH/NICHD grants R01 HD091218 and 3R01HD091218-04S1 (RADx-UP Supplement)

The outbreak caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in December 2019 has led to a global health crisis, causing more than 115 million infections and 2.5 million deaths worldwide. In March 2020, WHO declared a pandemic of coronavirus disease 2019 . The burden of disease has not been borne equally among the population, with more severe disease noted in the elderly, men, and those with cardiovascular comorbidities 1 2 3 4 . Initially the majority of studies to date suggest that COVID-19 did not cause increased mortality in pregnant women compared to non-pregnant women 5 . There are studies which do not support evidence of SARS-CoV-2 infection in the placenta and also disprove the possibility of vertical transmission and pregnancy-related complications 6 7 8 9 10 11 12 13 14 15 16 17 18 19 . However, a case report published early on in the pandemic showed the death of 7 pregnant women (out of 9), as well as one who was critically ill and one who recovered after prolonged hospitalization due to severe COVID-19 disease.

Comparison of severity of infection to family members of all 9 women showed disease severity in COVID-19 infected pregnant women 20 . Recent studies have reported that pregnant women are more likely to be positive for SARS-COV-2 and have both asymptomatic and severe disease outcomes as compared to nonpregnant women 21 22 23 24 25 . SARS-CoV-2 infection has been reported to put pregnant women and their fetuses at risk by increasing the possibility of pregnancy-related complications, including preeclampsia and Intrauterine growth restriction (IUGR) 23 26 27 28 29 30 31 . A number of recent studies now indicate increased risk for perinatal complications in pregnant patients with severe COVID-19 including higher incidence of preeclampsia and preterm birth in SARS-CoV-2 infected women 18 32 .

That said, the risk for vertical transmission 33 34 , although not nil, appears to be minimal 6 29 44 48 49 50 51 52 53 52 54 55 . A second-trimester miscarriage was reported in a case study of a woman with SARS-CoV-2 infection, and virus was found in placental sub membranes with immune cell infiltration in placental cotyledons 56 .

SARS-CoV-2 uses Angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor via viral Spike (S) protein, which binds the N-terminal peptidase domain of ACE2 57 58 59 . ACE2 is a key component of the Renin-Angiotensin system (RAS), a cascade of vasoactive peptides controlling angiogenesis, blood pressure, and fetal development by regulating inflammation 60 . Viral endocytosis into host cells is also mediated by Transmembrane protease, serine 2 (TMPRSS2), so maximum viral tropism for host cells depends on co-expression of ACE2 and TMPRSS2 57 58 59 . Notably, placental trophoblasts are highly responsive to the changes in angiotensin receptor concentrations that occur during pregnancy 60 61 . Expression of ACE2 and TMPRSS2 has been found during early pregnancy at the maternal-fetal interface in villous cytotrophoblasts (CTBs), STBs, and extravillous trophoblast cells (EVTs), but ACE2 expression decreases as the pregnancy progresses 44 62 63 . Although some doubts have been raised regarding whether ACE2 is present in the placenta 64 , a number of recent studies have confirmed the expression of ACE2 in placental cells 49 50 65 66 67 68 . The mechanism by which expression of ACE2 changes in the context of COVID-19 remains to be fully elucidated. The objective of our study was to determine whether SARS-CoV-2 affects expression of ACE2 in the placenta, and if so, whether alterations in ACE2 impacts the RAS system which can contribute to pregnancy outcomes.

Here, we report SARS-CoV-2 colonization in term and preterm placentas from SARS-CoV-2 positive women. SARS-CoV-2 was found in all placental sections, colonizing the basal plate (BP) in EVTs, villous tissue (VT) in STBs and HCs, subchorionic (SC) region, amniotic epithelium of fetal membrane (FM) and tunica adventitia layer of umbilical cord (UC). Intracellular virus was found in placental trophoblasts and HCs expressing ACE2. Histopathological analyses showed that SARS-CoV-2 infected preterm placentas harbored inflammatory infiltrates, whereas inflammation was negligibly J o u r n a l P r e -p r o o f present in non-infected preterm or any term placentas. Transfection of human trophoblasts with SARS-CoV-2 S protein or infection with a live modified virus with a vesicular stomatitis viral (VSV) backbone expressing SARS-CoV-2 S protein triggers downregulation of ACE2 receptor expression while increasing expression of AT 1 R and sFlt1, which are associated with preeclampsia pathogenesis. These findings were confirmed in SARS-CoV-2 infected pregnant patients. Thus, SARS-CoV-2, likely via viral Spike protein, disrupts the placental RAS pathway. In sum, we demonstrate that SARS-CoV-2 colonizes fetal trophoblasts, stromal cells, and macrophages in the placenta which express the ACE2 receptor. Spike binding to ACE2 leads to reduction of the receptor expression and results in alterations of the RAS pathway-changes that are similar to those typically noted in preeclampsia.

In our study, we used five placentas each from SARS-CoV-2 uninfected and SARS-CoV-2 infected pregnant women. Of the five SARS-CoV-2 infected women, three were asymptomatic, one had only anosmia and one had cough, dyspnea, chest pain, nausea/vomiting (n/v), and chills. SARS-CoV-2 infection was confirmed by qRT-PCR using nasopharyngeal swabs or saliva. There were no significant demographic differences between cases with positive maternal SARS-CoV-2 testing and our controls, and maternal age ranged from 19-33 years (uninfected) and 17-32 years (infected) ( Table 1) . One patient (20%) in both the infected and uninfected groups delivered preterm and three (60%) in both groups delivered vaginally. With the exception of one patient who tested positive and was symptomatic prior to delivery, the patients were positive at delivery. In addition, 3/5 (60%) pregnant patients were diagnosed with chronic hypertension, preeclampsia with severe features or gestational hypertension. CoV-2 in the placenta 49 50 69 . However, we determined that the virus was also found in fetal macrophages present in villous capillaries (Fig. 1C left inset, 1I right inset), stromal cells of the chorionic plate, (Fig. 1D, 1J) , and amniotic epithelial cells of the fetal membrane (Fig. 1E, 1K) . Finally, we note evidence of the virus in the tunica adventitial layer of the umbilical cord (Fig. 1F, 1L) . Together, our findings indicate that the virus can colonize multiple compartments at the maternal-fetal interface, including trophoblasts, stromal cells, immune cells, and epithelial cells.

The preterm placenta delivered at 23 weeks and 5 days harbored an abundance of S protein in EVTs ( Fig. 2A, 2G ) and in STBs and HCs (Fig. 2B, 2C, 2H) . SARS-CoV-2 S RNA and protein were present in higher abundance in stromal cells of the SC (Fig. 2D, 2I) , amniotic epithelial cells (Fig. 2E,   2J ), and the umbilical cord (Fig. 2F inset, 2K) . These findings indicate that SARS-CoV-2 can colonize all compartments at the maternal-fetal interface even earlier in gestation. Indeed, severity of SARS-J o u r n a l P r e -p r o o f CoV-2 infection appears to be greater in preterm than term tissue as observed by RNA-ISH staining of SARS-CoV-2-Spike ( Fig. 1 and 2) . Consistent with this, pathological changes were evident in the preterm placenta relative to term placentas. The term placentas did not show any significant histopathological changes (Fig. 3A-E left panel) . However, the preterm placenta had trophoblast giant cells in the BP (Fig. 3A right panel) but no changes in VT (Fig. 3B right panel) . The subchorion harbored infiltration of neutrophils indicative of increased inflammation (Fig. 3C right panel) . The fetal membrane showed amniotic edema and acute chorioamnionitis (inset, Fig. 3D right panel) , and the presence of necrotic amniocytes in addition to pigmented macrophages (Fig. 3D right panel) . The umbilical cord revealed acute funisitis or vasculitis ( Fig. 3E right panel) . There was no histological correlation between asymptomatic versus symptomatic placentas of SARS-CoV-2 positive women.

SARS-CoV-2 uses ACE2 as entry receptor, which is abundantly expressed in different organs of the body 70 71 72 73 . A few studies predating the pandemic have suggested that the placenta is no exception 74 75 . Here, using IHC with antibodies to ACE2, we analyzed SARS-CoV-2 positive and negative and preterm and term placentas for localization of ACE2 in multiple compartments. We found 

protein and an intact and cell surface localized ACE2 leads to the internalization of ACE2, which facilitates SARS-CoV-2 entry into host cells resulting in infection 76 . Semi quantitative analysis of IHC images of infected ( Fig. 4D-4F ) versus uninfected placental sections (Fig. 4A-4C ) showed a significant reduction in the level of ACE2 expression after SARS-CoV-2 infection (Fig. 4G) . A similar observation was found after Western blotting quantification of ACE2 levels in SARS-CoV-2 positive and uninfected term placentas (Fig. 4H left panel) . Furthermore, ACE2 levels were relatively lower in preterm J o u r n a l P r e -p r o o f placenta, and severe infection was associated with a greater decrease (Fig. 4H right panel) . Thus, not only does the placenta express the viral entry receptor ACE2, it is actively responsive to infection which results in its downregulation, which is itself indicative of infection.

The RAS is a complex cascade of vasoactive peptides controlling angiogenesis, blood pressure and fetal development and is made up of two major axes: inflammatory Angiotensin II (Ang II)/ (AT 1 R) (vasoconstrictive) and the anti-inflammatory protective axis ACE2/Ang-(1-7) (AT 2 R) (vasodilatory) 77 .

SARS-CoV-2 entry via ACE2 causes downregulation of membrane-bound ACE2 78 in other tissues, an occurrence we now show is recapitulated in the placenta. We reasoned that reduced ACE2 due to SARS-CoV-2 infection could impact the RAS system. Impaired RAS function and increase in the inflammatory AT 1 R could lead to increased production of preeclampsia markers, including soluble fmslike tyrosine kinase-1 (sFlt1) 79 80 81 82 . Consistent with this, we observed increased levels of sFlt1 in the pre-delivery sera of SARS-CoV-2 infected versus uninfected pregnant women (Fig. 4I) . Preeclampsia is associated with increased serum secretion of an auto-antibody (AT 1 -AA) that stimulates the AT 1 R receptor on trophoblasts where it synergistically acts with Ang II to impair RAS function, leading to increased production of sFlt1 79 80 81 82 . Indeed, we note that the pre-delivery sera of SARS-CoV-2 infected women exhibited significantly increased levels of AT1 autoantibodies (Fig. 4J) . Furthermore, the patients with increased AT1-AA and sFLT1 were diagnosed with chronic hypertension or gestational hypertension.

It has been shown that the viral Spike protein can induce internalization of ACE2, which initiates the fusion of viral particles and host cells 76 77 83 84 85 . To model the complex interaction between host receptor and viral spike protein and investigate the mechanistic link with RAS pathway activity, we treated placental trophoblast cells (JEG-3 cells) with the recombinant SARS-CoV-2 Spike protein in culture. We noted a significant reduction in the expression of ACE2 at 3 and 6 h post Spike protein J o u r n a l P r e -p r o o f treatment compared to untreated control cells (Fig. 5A) . Immunofluorescence staining and Western blotting for ACE2 showed that Spike treatment leads to reduction of ACE2 levels in placental cells corroborating our placental data (Fig. 5C, 5D ).

In addition, to model whole virus interaction with ACE2 in placental cells, we also employed a replication-competent virus to study entry and neutralization of SARS-CoV-2 86 shows a significant reduction in the expression of ACE2 at all the time points (1, 3 and 6 h) studied compared to 0 h control cells (Fig. 5B) . Immunofluorescence analysis confirmed that the expression of ACE2 is reduced after VSV-eGFP-SARS-CoV-2-S infection (Fig. 5E) . Together, these cellular findings confirmed that viral Spike protein interaction with ACE2 on placental cells leads to ACE2 downregulation. Next, we determined the consequences of ACE2 decrease on RAS activity in placental trophoblasts. We found a significant increase in expression of the inflammatory Angiotensin II type 1 receptor 1 (AT 1 R) (1 h) after the addition of recombinant SARS-CoV-2 spike protein; expression of AT 1 R was significantly high at all time points compared to 0 h JEG-3 cells (Suppl Fig. 1A) . We confirmed the same findings in the presence of VSV-eGFP-SARS-CoV-2-S infection at 1 MOI as compared to 0 h control (Suppl Fig. 1B) . In contrast, expression of the protective Angiotensin II type 1 receptor 2 (AT 2 R) and placental growth factor (PlGF) was significantly downregulated after Spike treatment (Suppl Fig. 1C, 1E) and VSV-eGFP-SARS-CoV-2-S infection (Suppl Fig. 1D, 1F) . Spike protein treatment was sufficient to induce a significant increase in sFlt1 (Suppl Fig. 1G) . Furthermore, levels of sFlt1 were upregulated after VSV-eGFP-SARS-CoV-2-S at 1 and 3 h of infection compared to uninfected controls (Suppl Fig. 1H) . The data here strongly suggest that even in the absence of viral nucleic acid, the presence of SARS-CoV-2 Spike antigen is enough to induce preeclamptic signatory markers in trophoblasts.

Together, our in vitro and tissue findings demonstrate that SARS-CoV-2 infection leads to reduced expression of ACE2, resulting in downregulation of the protective AT 2 R and PIGF and upregulation of the proinflammatory AT 1 R, AT 1 -AA and sFlt1 arms of the RAS cascade.

In this study, we detected both viral Spike RNA and protein in all five placentas (four term and one preterm) from SARS-CoV-2-infected women. We described the presence of SARS-CoV-2 Spike HCs can also induce immunomodulatory cytokines that limit viral replication 87 88 89 90 91 .

The high affinity of SARS-CoV-2 towards ACE2 aids in viral entry that subsequently triggers downregulation of ACE2 expression, disrupting the equilibrium of the RAS pathway 76 77 92 . The importance of ACE2 and RAS in pregnancy is supported by several pieces of evidence. First, J o u r n a l P r e -p r o o f expression of renin and angiotensin increases as pregnancy progresses 93 . Second, mice lacking Ace2 exhibit placental dysfunction as evidenced by abnormal uterine remodeling, placental hypoxia, and uterine artery reactivity to vasoconstrictors 94 . Third, the circulating levels of renin and angiotensin 1 are lower in women with preeclampsia than in normotensive women 95 . Fourth, ACE2 is expressed in multiple cells types throughout the body and its expression can be altered due to pregnancy. A recent study showed the downregulation of ACE2 in the nasal epithelium of pregnant rats compared with nonpregnant rats 96 . Finally, reduction in ACE2 can pivot the RAS to become more inflammatory with Medicine Units (MFMU) Network suggest that patients with severe COVID19 are at increased risk of perinatal complications 22, 31 . In sum, our study provides the foundation to understand the mechanism by which SARS-CoV-2 affects pregnancy by downregulating ACE2 expression in placental trophoblast cells and subsequently dysregulating the RAS pathway. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Indira U. Mysorekar (imysorekar@wustl.edu).

This study did not generate new unique reagents.

This study did not generate any unique datasets or code.

This study was approved by Washington University School of Medicine Institutional Review Board (IRB #202003130). Informed consent has been signed by all the subjects involved in the study. Selected patient demographic data and institutional pathology reports were collected for all cases and controls.

Universal testing for SARS-CoV-2 by PCR of nasopharyngeal swabs and later saliva was performed for all women admitted to our labor and delivery service at the Barnes Jewish Hospital. Placental samples and blood were collected from women who tested positive at the time of delivery, and contemporary controls who tested negative. (Suppl table- 1) 106 . Experiments were performed under biosafety level 2 (BSL2) conditions.

JEG-3 cells were purchased from ATCC (HB-36) and grown in 10% DMEM/F12 media at 37°C, 5%

CO2 and 70% relative humidity as described in 107 Amplification of signal was performed using Amp1-6 probes for single staining and Amp1-10 for dual staining. Slides were counterstained using Hematoxylin and mounted using Eco mount solution. Slides were scanned using standard bright field Nikon Eclipse E800 microscope.

Tissue section slides of various parts of the placenta were sequentially rehydrated using ethanol-water Optical density was measured using microplate reader at 450 nm and 540 nm. The concentration of sFlt1 and AT 1 -AA was calculated using 4-parametric logistic curve-fit. The experiment was performed in duplicate.

Indirect immunofluorescence was performed to check infection of VSV-eGFP-SARS-CoV-2-S and the expression of ACE2. Briefly, JEG-3 cells were seeded in 2-chamber slides and kept overnight at 37°C, 5% CO 2 and 70% relative humidity. The next day, cells were infected/treated with VSV-eGFP-SARS- 

A systematic scoping review of COVID-19 during pregnancy and childbirth

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings

Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry?

Severe Coronavirus Infections in Pregnancy: A Systematic Review

Placental pathology of the third trimester pregnant women from COVID-19

Vertical Transmission of Coronavirus Disease 19 (COVID-19) from Infected Pregnant Mothers to Neonates: A Review

An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes

Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Maternal death due to COVID-19

Higher SARS-CoV-2 Infection Rate in Pregnant Patients

Disease Severity, Pregnancy Outcomes and Maternal Deaths among Pregnant Patients with SARS-CoV-2 Infection in Washington State

Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy -SET-NET, 16 Jurisdictions

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Report of Positive Placental Swabs for SARS-CoV-2 in an Asymptomatic Pregnant Woman with COVID-19

SARS-CoV2 and pregnancy: An invisible enemy?

Impact of SARS-CoV-2 on multiple gestation pregnancy

COVID-19 in pregnant women: A systematic review and meta-analysis

Vertical transmission of SARS-CoV-2 infection and preterm birth

Preterm delivery, maternal death, and vertical transmission in a pregnant woman with COVID-19 infection

COVID-19 Infection and Hypertensive Disorders of Pregnancy

Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19)

Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection

Vertical transmission of coronavirus disease 2019: severe acute respiratory syndrome coronavirus 2 RNA on the fetal side of the placenta in pregnancies with coronavirus disease 2019-positive mothers and neonates at birth

Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study

A Case Report of Neonatal 2019 Coronavirus Disease in China

Antibodies in Infants Born to Mothers With COVID-19 Pneumonia

Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study

Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn

Infants Born to Mothers With a New Coronavirus (COVID-19). Front Pediatr 8

Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019

SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review

Placental Pathology in COVID-19

SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

Histopathology of Third Trimester Placenta from SARS-CoV-2-Positive Women. medRxiv

Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China

Connecting the dots on vertical transmission of SARS-CoV-2 using protein-protein interaction network analysis -Potential roles of placental ACE2 and ENDOU

Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2

SARS-CoV-2 infection of the placenta

Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-fetal dyads

SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta

SARS-CoV-2 placentitis: An uncommon complication of maternal COVID-19

Placental SARS-CoV-2 in a pregnant woman with mild COVID-19 disease

Description of a late miscarriage case at 16 Weeks of Gestation associated with a SARS-CoV-2 infection

Detection of severe acute respiratory syndrome coronavirus 2 in placental and fetal membrane samples

Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

The functional role of the renin-angiotensin system in pregnancy and preeclampsia

Causes and Consequences of the Dysregulated Maternal Renin-Angiotensin System in Preeclampsia

Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia

Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester

Does the human placenta express the canonical cell entry mediators for SARS-CoV-2? Elife 9

Single-Cell RNA-seq Identifies Cell Subsets in Human Placenta That Highly Expresses Factors Driving Pathogenesis of SARS-CoV-2

SARS-CoV-2 Entry Factors: ACE2 and TMPRSS2 Are Expressed in Peri-Implantation Embryos and the Maternal-Fetal Interface

Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic

Placental barrier against COVID-19

Placental Pathology Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based cardiovascular therapies

The protein expression profile of ACE2 in human tissues

Why are pregnant women susceptible to COVID-19? An immunological viewpoint

A Message from the Human Placenta: Structural and Immunomodulatory Defense against SARS-CoV-2

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Covid-19: the renin-angiotensin system imbalance hypothesis

Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications

From mother to child--transplacental effect of AT1R-AA in preeclampsia

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Circulating angiogenic factors and the risk of preeclampsia

Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia

TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Placental Hofbauer cells limit HIV-1 replication and potentially offset mother to child transmission (MTCT) by induction of immunoregulatory cytokines

Viral infection, proliferation, and hyperplasia of Hofbauer cells and absence of inflammation characterize the placental pathology of fetuses with congenital Zika virus infection

Zika virus infection of Hofbauer cells

The Elusive Role of Placental Macrophages: The Hofbauer Cell

Viral-Immune Cell Interactions at the Maternal-Fetal Interface in Human Pregnancy

SARS-CoV-2 as a Factor to Disbalance the Renin-Angiotensin System: A Suspect in the Case of Exacerbated IL-6 Production

Single-cell transcriptomics of the human placenta: inferring the cell communication network of the maternal-fetal interface

Uterine artery dysfunction in pregnant ACE2 knockout mice is associated with placental hypoxia and reduced umbilical blood flow velocity

Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies

Reduced severe acute respiratory syndrome coronavirus 2 entry factors and enhanced innate immune gene expression in the nasal epithelium of pregnant rats

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirusinduced lung injury

Much More Than Just a Receptor for SARS-COV-2

Increased sFLT-1/PlGF ratio in COVID-19: A novel link to angiotensin IImediated endothelial dysfunction

Maternal Coronavirus Infections and Neonates Born to Mothers with SARS-CoV-2: A Systematic Review

The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection

Spanish Group for the Study of Angiogenic Markers in

PlGF Ratio in Singleton Pregnancies

Association of SARS-CoV-2 Test Status and Pregnancy Outcomes

Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study

Quantitative RT-PCR for titration of replication-defective recombinant Semliki Forest virus

Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice